In an adult kidney‑transplant recipient receiving standard immunosuppression (tacrolimus or cyclosporine, mycophenolate, prednisone), how should Journavx (suzetrigine) be dosed, monitored, and adjusted for renal impairment, and what alternative analgesics are recommended if severe renal dysfunction precludes its use?

Journavx Use in Kidney Transplant Recipients

There is no available evidence regarding Journavx (suzetrigine) use specifically in kidney transplant recipients, but based on FDA labeling, avoid Journavx in patients with severe renal impairment (eGFR <15 mL/min) and use standard dosing for eGFR >15 mL/min with close monitoring of graft function. 1

Critical Dosing Information from FDA Label

Renal Impairment Considerations

• Contraindicated: eGFR <15 mL/min 1
• Standard dosing permitted: eGFR >15 mL/min (same as normal kidney function) 1
• No dose adjustment needed for mild-to-moderate renal impairment in the FDA label

Standard Dosing Regimen

• Initial dose: 100 mg orally on empty stomach (1 hour before or 2 hours after food) 1
• Maintenance: 50 mg every 12 hours starting 12 hours after initial dose 1
• Duration: Use shortest duration consistent with treatment goals; not studied beyond 14 days 1

Drug Interaction Concerns in Transplant Patients

CYP3A Interactions

Journavx is contraindicated with strong CYP3A inhibitors 1. This is particularly relevant because:

• Many transplant patients may receive azole antifungals or other strong CYP3A inhibitors
• With moderate CYP3A inhibitors, reduce dosing to 50 mg every 24 hours after the first 4 doses 1
• Avoid grapefruit during treatment 1

Immunosuppressant Monitoring

While Journavx has no documented interactions with tacrolimus, cyclosporine, or mycophenolate, the KDIGO guidelines emphasize measuring CNI blood levels whenever there is a change in medication or patient status that may affect blood levels 2. Therefore:

• Monitor tacrolimus/cyclosporine trough levels more frequently when initiating Journavx
• Watch for any decline in kidney function that may indicate nephrotoxicity 2

Monitoring Strategy

Renal Function Surveillance

Given the lack of specific data in transplant recipients and the FDA's limited study in severe renal impairment:

• Measure serum creatinine at baseline before starting Journavx
• Recheck creatinine within 3-7 days of initiation
• Monitor for AKI (creatinine increase ≥50% or ≥26.5 μmol/L from baseline) 3
• Follow KDIGO recommendations for routine creatinine monitoring in transplant recipients 2

Additional Monitoring

• Creatine phosphokinase (CPK): Journavx can cause elevated CPK and muscle spasms 1
• Potassium levels: Particularly important given baseline immunosuppression effects

Alternative Analgesics When Journavx is Precluded

When to Use Alternatives

• eGFR <15 mL/min (absolute contraindication) 1
• Severe hepatic impairment (Child-Pugh Class C) 1
• Concurrent strong CYP3A inhibitor use 1

Recommended Alternatives Based on Evidence

Opioid Options (from SPAQI guidelines) 4:

1. Preferred in renal insufficiency/ESRD:

   • Fentanyl (no active metabolites)
   • Sufentanil (no active metabolites)
   • Methadone (requires experienced clinician)

2. Use with caution (adjust dose in GFR <30):

   • Hydrocodone
   • Oxycodone
   • Hydromorphone

3. Avoid completely:

   • Meperidine (active metabolites accumulate) 4
   • Codeine (active metabolites accumulate) 4
   • Morphine (active metabolites accumulate) 4
   • Tramadol (not recommended in GFR <30) 4

NSAIDs: Should be avoided in kidney transplant recipients due to nephrotoxicity risk 5, 3. Despite this, 11% of transplant recipients receive NSAID prescriptions 3, highlighting a common but inappropriate practice.

Critical Pitfalls to Avoid

1. Do not assume Journavx is safe simply because the FDA label allows use in eGFR >15 mL/min—this was not specifically studied in transplant recipients with immunosuppression
2. Do not overlook drug interactions with azole antifungals or other CYP3A inhibitors commonly used post-transplant
3. Do not prescribe NSAIDs as alternatives—30% of transplant recipients are unaware of NSAID risks 5
4. Do not use codeine, tramadol, or meperidine in patients with compromised renal function 4

Practical Clinical Algorithm

For kidney transplant recipients needing acute pain management:

1. Assess eGFR and hepatic function

   • eGFR <15 mL/min → Avoid Journavx, use fentanyl/sufentanil
   • eGFR >15 mL/min → May proceed with caution

2. Review concurrent medications

   • Strong CYP3A inhibitor → Contraindicated, use opioid alternative
   • Moderate CYP3A inhibitor → Reduce Journavx to daily dosing after 4 doses

3. If using Journavx:

   • Standard dosing per FDA label
   • Check creatinine within 3-7 days
   • Monitor CNI levels within 1 week
   • Check CPK if muscle symptoms develop

4. If Journavx contraindicated:

   • First-line: Fentanyl or sufentanil (no renal dose adjustment needed)
   • Second-line: Hydromorphone with dose reduction
   • Avoid: NSAIDs, meperidine, codeine, morphine, tramadol